期刊文献+

乳腺黏液癌HER2基因表达特征分析 被引量:3

原文传递
导出
摘要 HER2阳性的浸润性乳腺癌患者预后较差,而乳腺黏液癌是浸润性乳腺癌中一种少见的特殊类型,约占乳腺癌的4%左右,被分为单纯型和混合型,其中单纯型黏液癌( puremucinous breast carcinoma, PMBC)中黏液癌成分〉90%或全部由黏液癌组成;混合型黏液癌(mixed mucinous breast carcinoma, MMBC)则包含有他浸润性癌的成分。PMBC的5年无病生存率几乎为100%,其免疫表型通常表现为雌激素受体(ER)、孕激素受体(PR)阳性而HER2阴性。然而,随着荧光原位杂交(FISH)技术在乳腺癌HER2基因扩增检测中的普遍应用,在实际工作中我们发现一些黏液癌中也存在HER2阳性,我们采用免疫组织化学和FISH方法分析乳腺黏液癌HER2基因的表达特征。
出处 《中华病理学杂志》 CAS CSCD 北大核心 2015年第4期278-279,共2页 Chinese Journal of Pathology
  • 相关文献

参考文献11

  • 1Lakhani SR,Ellis IO,Schnitt SJ,et al.WHO Classification of tumours of the breast[M].4th ed.Lyon:IARC Press,2012.
  • 2Edge SB,Byrd DR,Compton CC,et al.AJCC Cancer staging Manual[M].7th ed.New York:Springer,2009.
  • 3乳腺癌HER2检测指南(2014版)[J].中华病理学杂志,2014,43(4):262-267. 被引量:295
  • 4Barbashina V,Corben AD,Akram M,et al.Time to change the way we diagnose mucinous carcinomas of breast:reply[J].Hum Pathol,2014,45(2):435.
  • 5Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
  • 6WoIff AC,Hammond ME,Hicks DG,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol,2013,31(31):3997-4013.
  • 7杨飞,杨文涛,步宏.乳腺癌HER2检测中的新问题[J].中华病理学杂志,2012,41(5):289-292. 被引量:12
  • 8王炜,项晶晶,崔海东,刘坚,徐如君.乳腺癌患者HER2基因检测——带着问题重读《ASCO/CAP指南》[J].中华外科杂志,2013,51(10):875-878. 被引量:5
  • 9Hanna WM,Riischoff J,Bilous M,et al.HER2 in situ hybridization in breast cancer:clinical implications of polysomy 17 and genetic heterogeneity[J].Mod Pathol,2014,27(1):4-18.
  • 10蔺会云,皋岚湘,金木兰,丁华野.以微乳头状结构为特点的乳腺单纯型黏液癌临床病理观察[J].中华病理学杂志,2012,41(9):613-617. 被引量:25

二级参考文献80

  • 1郭晓静,陈凌,郎荣刚,范宇,付丽.乳腺浸润性微乳头状癌的病理学特征与淋巴结转移的关系[J].中华病理学杂志,2006,35(1):8-12. 被引量:34
  • 2张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 4陈凌,范宇,郎荣刚,郭晓静,孙玉兰,付丽.伴有浸润性微乳头状癌结构乳腺癌的诊断和预后研究[J].中华病理学杂志,2007,36(4):228-232. 被引量:17
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007,131 (1): 18-43.
  • 6Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol, 1999, 17(7) : 1983-1987.
  • 7Perez EA, Dueck AC, MeCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/ CAP HER2-positivity criteria. J Natl Cancer Inst, 2012, 104(2) : 159-162.
  • 8Ragi A. Human epidermal growth factor receptor 2 testing recommendation. J Clin Oncol, 2007, 25 (25) : 4020-4021.
  • 9Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol, 2011,29 (15) : e458.
  • 10Vance GH, Barry TS, Bloom K J, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med, 2009, 133(4) : 611-612.

共引文献325

同被引文献29

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部